Navigation Links
Aethlon Medical Clarifies News Report
Date:4/20/2011

SAN DIEGO, April 20, 2011 /PRNewswire/ -- Earlier today, Aethlon Medical, Inc. (OTCBB: AEMD) disclosed that it was the subject of an ABC affiliate station news story that included discussion of the company's proposed strategy to reduce the occurrence of sepsis in wounded military personnel.  As previously disclosed, the company submitted a contract response on April 1, 2011 to a Broad Agency Announcement (BAA) entitled Dialysis Like Therapeutics (DLT).  In the submission, company proposed multiple capabilities including the development of dialysis-like therapy that would address the objectives of the DLT program.  The company wishes to clarify that there is no assurance it will be invited to participate in the DLT program and that battlefield deployment of such a device is not feasible in the near future as suggested in the ABC affiliate news story.  However, the company does believe that successful clinical outcomes in treating Hepatitis-C (HCV) infected patients with its Hemopurifier® technology does offer the potential for an early commercialization pathway of its Hemopurifier® in India.  The company appreciates the coverage by the ABC news affiliate which unfortunately confused the potential commercialization timeline of our Hemopurifier® with the device proposed to be developed in our DLT response.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.  Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.  We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer.  Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care.  By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens.  In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats.  These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer:  A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV):  As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions.  As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses.  These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device.  The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system.  In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device.  Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI), is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy.  Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, including obtaining government grants, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier® to improve the efficacy of SOC therapy against HCV, the Company's ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier®, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contacts:

James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... UNION CITY, Calif. , April 24, 2017 /PRNewswire/ ... providing durability, grip, protection, and comfort, announces the release ... the Powerform S8+. This most recent example of leading ... high density grip pattern for 200% more tactile grip ... in user protection and durability. With TracTek and a ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:4/20/2017)...   ZappRx, Inc ., a digital health company focused ... announced it closed $25 million in Series B funding led ... in Seattle that is part of ... Series B round included participation from SR One , ... GV (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of a ... Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. By ... to a patient’s remote health progress, empowering the patient to take direct responsibility for ...
(Date:4/26/2017)... ... ... RawTrition now brings you BioEnergy which is a powder capsule whole food ... RawTrition is taking nutrients to the next level! The superfoods in RawTrition's BioEnergy ... (unlike the synthetically made options that are on the market). , Founder of RawTrition, ...
(Date:4/25/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically ... aging, and minimize the appearance of pores – all with minimal downtime and ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... and HR decision-makers are preparing for how his administration could impact the employee ... insight into what changes are most likely to make it through Congress. His ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... rely on contracted partners to help with process innovation in drug formulation and ... formulation experience along with state-of-the-art analytical equipment in support of their development and ...
Breaking Medicine News(10 mins):